Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-37812
Titel: Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy : a multicenter cohort study
VerfasserIn: Kornienko, Kira
Siegel, Fabian
Borkowetz, Angelika
Hoffmann, Manuela A.
Drerup, Martin
Lieb, Verena
Bruendl, Johannes
Höfner, Thomas
Cash, Hannes
von Hardenberg, Jost
Westhoff, Niklas
Sprache: Englisch
Titel: Prostate Cancer and Prostatic Diseases
Bandnummer: 25 (2022)
Heft: 1
Seiten: 109–116
Verlag/Plattform: Springer Nature
Erscheinungsjahr: 2021
Freie Schlagwörter: Prostate cancer
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Background Although multiparametric magnetic resonance imaging (mpMRI) is recommended for primary risk stratification and follow-up in Active Surveillance (AS), it is not part of common AS inclusion criteria. The objective was to compare AS eligibility by systematic biopsy (SB) and combined MRI-targeted (MRI-TB) and SB within real-world data using current AS guidelines. Methods A retrospective multicenter study was conducted by a German prostate cancer (PCa) working group representing six tertiary referral centers and one outpatient practice. Men with PCa and at least one MRI-visible lesion according to Prostate Imaging Reporting and Data System (PI-RADS) v2 were included. Twenty different AS inclusion criteria of international guidelines were applied to calculate AS eligibility using either a SB or a combined MRI-TB and SB. Reasons for AS exclusion were assessed. Results Of 1941 patients with PCa, per guideline, 583–1112 patients with PCa in both MRI-TB and SB were available for analysis. Using SB, a median of 22.1% (range 6.4–72.4%) were eligible for AS. Using the combined approach, a median of 15% (range 1.7–68.3%) were eligible for AS. Addition of MRI-TB led to a 32.1% reduction of suitable patients. Besides Gleason Score upgrading, the maximum number of positive cores were the most frequent exclusion criterion. Variability in MRI and biopsy protocols potentially limit the results. Conclusions Only a moderate number of patients with PCa can be monitored by AS to defer active treatment using current guidelines for inclusion in a real-world setting. By an additional MRI-TB, this number is markedly reduced. These results underline the need for a contemporary adjustment of AS inclusion criteria.
DOI der Erstveröffentlichung: 10.1038/s41391-021-00478-2
URL der Erstveröffentlichung: https://www.nature.com/articles/s41391-021-00478-2
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-378120
hdl:20.500.11880/34195
http://dx.doi.org/10.22028/D291-37812
ISSN: 1476-5608
1365-7852
Datum des Eintrags: 3-Nov-2022
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Urologie und Kinderurologie
Professur: M - Prof. Dr. Michael Stöckle
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
s41391-021-00478-2.pdf918,36 kBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons